Source - Alliance News

4basebio PLC - Heidelberg, Germany-based life sciences company - Teams up with the University of Alabama and England-based Teesside University for a research project on Neurofibromatosis type 1, or NF1. The two universities have received $1 million from US-based Gilbert Family Foundation for a three-year research programme. It aims to ‘life-changing gene therapy with applicability to all NF1 patients,’ 4basebio says. The firm will produce a non-viral vector for the universities, it adds.

‘NF1 is a genetic condition which causes usually benign tumours to develop anywhere in the nervous system, including the brain, spinal cord and nerves. Complications of NF1 are many and can include learning difficulties, speech difficulties and skeletal malformations, heart and blood vessel (cardiovascular) problems, loss of vision, and severe pain. NF1 is caused by mutations in the NF1 gene which regulates the production of neurofibromin protein,’ company explains.

Current stock price: 477.00 pence, up 2.6% on Friday

12-month change: up 18%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

4Basebio PLC (4BB)

+15.00p (+2.07%)
delayed 16:57PM